Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Non-benzimidazole containing inhibitors of respiratory syncytial virus.

Pryde DC, Tran TD, Gardner I, Bright H, Stupple P, Galan S, Alsop L, Watson L, Middleton DS, Dayal S, Platts M, Murray EJ, Parkinson T, Webster R.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):827-33. doi: 10.1016/j.bmcl.2012.11.062. Epub 2012 Nov 29.

PMID:
23265891
2.

Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity.

Wang XA, Cianci CW, Yu KL, Combrink KD, Thuring JW, Zhang Y, Civiello RL, Kadow KF, Roach J, Li Z, Langley DR, Krystal M, Meanwell NA.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4592-8. Epub 2007 Jun 8.

PMID:
17576060
3.

Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives.

Yu KL, Zhang Y, Civiello RL, Trehan AK, Pearce BC, Yin Z, Combrink KD, Gulgeze HB, Wang XA, Kadow KF, Cianci CW, Krystal M, Meanwell NA.

Bioorg Med Chem Lett. 2004 Mar 8;14(5):1133-7.

PMID:
14980651
4.

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship.

Bonfanti JF, Doublet F, Fortin J, Lacrampe J, Guillemont J, Muller P, Queguiner L, Arnoult E, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, Janssens F, Sommen C, Wigerinck P, Andries K.

J Med Chem. 2007 Sep 20;50(19):4572-84. Epub 2007 Aug 28.

PMID:
17722899
5.

Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo.

Yu KL, Wang XA, Civiello RL, Trehan AK, Pearce BC, Yin Z, Combrink KD, Gulgeze HB, Zhang Y, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Wyde PR, Krystal M, Meanwell NA.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1115-22. Epub 2005 Dec 20.

PMID:
16368233
6.

Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor.

Yu KL, Zhang Y, Civiello RL, Kadow KF, Cianci C, Krystal M, Meanwell NA.

Bioorg Med Chem Lett. 2003 Jul 7;13(13):2141-4.

PMID:
12798322
7.

Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo.

Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4857-62. doi: 10.1016/j.bmcl.2009.06.030. Epub 2009 Jun 13.

PMID:
19596574
8.

Novel pyrrolo- and thiazolo-imidazoles.

Chimirri A, Grasso S, Monforte AM, Monforte P, ZappalĂ  M.

Farmaco. 1995 Jun;50(6):401-4. Review.

PMID:
7669178
9.

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).

Bonfanti JF, Meyer C, Doublet F, Fortin J, Muller P, Queguiner L, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, van Remoortere P, Janssens F, Wigerinck P, Andries K.

J Med Chem. 2008 Feb 28;51(4):875-96. doi: 10.1021/jm701284j. Epub 2008 Feb 7.

PMID:
18254606
10.

1,4-Benzodiazepines as inhibitors of respiratory syncytial virus.

Carter MC, Alber DG, Baxter RC, Bithell SK, Budworth J, Chubb A, Cockerill GS, Dowdell VC, Henderson EA, Keegan SJ, Kelsey RD, Lockyer MJ, Stables JN, Wilson LJ, Powell KL.

J Med Chem. 2006 Apr 6;49(7):2311-9.

PMID:
16570927
11.

The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1.

Bond S, Draffan AG, Fenner JE, Lambert J, Lim CY, Lin B, Luttick A, Mitchell JP, Morton CJ, Nearn RH, Sanford V, Stanislawski PC, Tucker SP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):969-75. doi: 10.1016/j.bmcl.2014.11.018. Epub 2014 Nov 15.

PMID:
25595682
12.

The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus.

Nikitenko AA, Raifeld YE, Wang TZ.

Bioorg Med Chem Lett. 2001 Apr 23;11(8):1041-4.

PMID:
11327584
13.

Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.

Tonelli M, Novelli F, Tasso B, Vazzana I, Sparatore A, Boido V, Sparatore F, La Colla P, Sanna G, Giliberti G, Busonera B, Farci P, Ibba C, Loddo R.

Bioorg Med Chem. 2014 Sep 1;22(17):4893-909. doi: 10.1016/j.bmc.2014.06.043. Epub 2014 Jul 1.

PMID:
25082514
14.

Respiratory syncytial virus fusion inhibitors. Part 6: an examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety.

Combrink KD, Gulgeze HB, Thuring JW, Yu KL, Civiello RL, Zhang Y, Pearce BC, Yin Z, Langley DR, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Yang Z, Zadjura L, Krystal M, Meanwell NA.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4784-90. Epub 2007 Jun 26.

PMID:
17616396
15.

[Experimental research on anti-respiratory syncytial virus effect in vitro of earthworm coelomic fluid].

Li F, Wang JH, Zhang JL, Zhong RG, Niu B.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010 Apr;24(2):116-8. Chinese.

PMID:
21110430
16.

Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles.

Burgeson JR, Moore AL, Gharaibeh DN, Larson RA, Cerruti NR, Amberg SM, Hruby DE, Dai D.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):750-6. doi: 10.1016/j.bmcl.2012.11.093. Epub 2012 Dec 1.

PMID:
23265900
17.

Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability.

Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):895-901. Epub 2006 Dec 1. Erratum in: Bioorg Med Chem Lett. 2007 Apr 15;17(8):2385.

PMID:
17169560
18.

Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus.

Andries K, Moeremans M, Gevers T, Willebrords R, Sommen C, Lacrampe J, Janssens F, Wyde PR.

Antiviral Res. 2003 Nov;60(3):209-19.

PMID:
14638397
19.

Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.

Golankiewicz B, Januszczyk P, Ikeda S, Balzarini J, De Clercq E.

J Med Chem. 1995 Sep 1;38(18):3558-65. Erratum in: J Med Chem 1996 Jan 19;39(2):624.

PMID:
7658442
20.

1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate.

Bond S, Draffan AG, Fenner JE, Lambert J, Lim CY, Lin B, Luttick A, Mitchell JP, Morton CJ, Nearn RH, Sanford V, Anderson KH, Mayes PA, Tucker SP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):976-81. doi: 10.1016/j.bmcl.2014.11.024. Epub 2014 Nov 14.

PMID:
25595685
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk